RecruitingNCT06537752

A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients

A Multi-center, Prospective, Observational stuDy to Evaluate EThanOl-induced Symptoms and Safety in Breast Cancer Patients witH Neoadjuvant/Adjuvant Chemotherapy Including Non-ethanol Formulation Docetaxel Before and After Surgery


Sponsor

Boryung Pharmaceutical Co., Ltd

Enrollment

1,052 participants

Start Date

Jul 15, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to evaluate ethanol-induced symptoms and safety in breast cancer patients with neoadjuvant/adjuvant chemotherapy including Non-ethanol formulation docetaxel before and after surgery


Eligibility

Sex: FEMALEMin Age: 19 Years

Inclusion Criteria6

  • Those who voluntarily signed a written personal information collection and usage agreement after receiving an explanation about the objective and method, etc. of this clinical study.
  • Those are confirmed to have primary breast cancers through histological diagnosis and one of the following are applicable.
  • Those who need neoadjuvant chemotherapy as breast cancer patients
  • Those who need adjuvant chemotherapy after breast cancer surgery
  • Those who are scheduled to administer non-ethanol formulation docetaxel according to chemotherapy
  • Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

Exclusion Criteria3

  • Those are diagnosed with other primary cancer that can influence the treatment or prognosis of primary breast cancers.
  • Those are diagnosed with secondary breast cancers.
  • Those with Stage 0/1 (Tis, N0, M0) or Stage IV (any T, Any N, M1) breast cancers.

Locations(2)

Chung-Ang University Hospital

Seoul, South Korea

Uijeongbu Eulji Medical Center, Eulji University

Uijeongbu-si, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06537752


Related Trials